News
CVRX
5.25
-0.47%
-0.03
CVRx (CVRX) Q1 Loss Of US$13.1 Million Tests Bullish Revenue Growth Narrative
Simply Wall St · 14h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 21h ago
Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Personalis (PSNL)
TipRanks · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)
TipRanks · 1d ago
Canaccord Genuity Keeps Their Buy Rating on CVRx (CVRX)
TipRanks · 1d ago
Piper Sandler Sticks to Its Buy Rating for CVRx (CVRX)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Kyntra Bio (KYNB)
TipRanks · 1d ago
CVRx Earnings Call Highlights Growth Amid Ongoing Losses
TipRanks · 1d ago
CVRx signals $63M-$67M 2026 revenue outlook as Category I CPT transition reshapes prior authorization dynamics
Seeking Alpha · 1d ago
CVRx (CVRX) Q1 2026 Earnings Call Transcript
The Motley Fool · 1d ago
CVRx reports Q1 EPS (50c), consensus (50c)
TipRanks · 1d ago
CVRx sees Q2 revenue $15.1M-$16.1M, consensus $15.6M
TipRanks · 1d ago
CVRx GAAP EPS of -$0.50 in-line, revenue of $14.8M beats by $0.17M
Seeking Alpha · 1d ago
CVRx's Q1 revenue rises 20%, beats expectations
Reuters · 1d ago
Press Release: CVRx Reports First Quarter 2026 Financial and Operating Results
Dow Jones · 1d ago
CVRx: Q1 Earnings Snapshot
Barchart · 1d ago
Weekly Report: what happened at CVRX last week (0504-0508)?
Weekly Report · 2d ago
Lake Street Sticks to Its Buy Rating for CVRx (CVRX)
TipRanks · 05/05 13:36
CVRx enrolls first patient in BENEFIT-HF trial
TipRanks · 05/04 21:15
CVRx Enrolls First Participant In BENEFIT-HF Study To Evaluate Barostim
Benzinga · 05/04 20:42
More
Webull provides a variety of real-time CVRX stock news. You can receive the latest news about Cvrx, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.